Abstract
Tildrakizumab, a humanized IgG1κ monoclonal antibody that inhibits the p19 subunit of interleukin (IL-)23, is FDA approved for the treatment of moderate-to-severe plaque psoriasis. This article will review recent publications on tildrakizumab to evaluate its pharmacokinetics, efficacy, and safety. Tildrakizumab maintains efficacy in moderate-to-severe plaque psoriasis for up to 3 years with low risk of adverse events. IL-23p19 inhibition with tildrakizumab is a useful therapy for treating moderate-to-severe psoriasis. It is superior to placebo and etanercept in clinical trials as measured by Psoriasis Area Severity Index (PASI), Physician Global Assessment (PGA), and Dermatology Life Quality Index (DLQI) scores. Clinical improvements are maintained for up to 3 years. It has a low frequency of adverse events that is similar to placebo, with the most common being headache and nasopharyngitis. Tildrakizumab can be a useful therapeutic option for patients with plaque psoriasis resistant to phototherapy and other systemic medications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have